DrugPatentWatch Database Preview
PROBUPHINE Drug Profile
see a sample report or, see our see our flat-rate plans
When do Probuphine patents expire, and what generic alternatives are available?
This drug has ten patent family members in seven countries.
The generic ingredient in PROBUPHINE is buprenorphine hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride profile page.
Summary for PROBUPHINE
| International Patents: | 10 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 11 |
| Clinical Trials: | 7 |
| Patent Applications: | 4,620 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | PROBUPHINE at DailyMed |
Pharmacology for PROBUPHINE
| Drug Class | Partial Opioid Agonist |
| Mechanism of Action | Partial Opioid Agonists |
Synonyms for PROBUPHINE
| (-)-buprenorphine |
| (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7(12),8,10-trien-11-ol |
| (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1;{2,8}.0;{1,6}.0;{6,14}.0;{7,12}]icosa-7,9,11-trien-11-ol |
| (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol |
| (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol |
| [5alpha,7alpha(S)]- |
| [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol |
| 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol |
| 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol |
| 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol |
| 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol |
| 2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol |
| 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine |
| 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine |
| 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine |
| 40D3SCR4GZ |
| 52485-79-7 |
| 53152-21-9 (hydrochloride) |
| 6,14-ethenomorphinan-3-ol, 17-(cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-7-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,7alpha)- |
| 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, |
| 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5-alpha,7-alpha-(S))- |
| 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)- (9CI) |
| 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI) |
| 6029-M |
| AC1LD8IH |
| BDBM50026603 |
| BEMA |
| Buprel |
| Buprenex |
| Buprenex (TN) |
| Buprenex, Subutex, Suboxone, Butrans |
| Buprenophine |
| Buprenorfina |
| Buprenorfina [INN-Spanish] |
| buprenorfine |
| buprenorphine |
| Buprenorphine (JAN/INN) |
| Buprenorphine [INN:BAN:JAN] |
| Buprenorphine [INN:BAN] |
| Buprenorphine Hcl |
| Buprenorphinum |
| Buprenorphinum [INN-Latin] |
| Butrans |
| C-22673 |
| C08007 |
| CAM2038 |
| CC-25269 |
| CHEBI:3216 |
| CHEMBL560511 |
| D06AWE |
| DB00921 |
| DEA No. 9064 |
| DTXSID2022705 |
| EINECS 257-950-6 |
| GTPL1670 |
| Norspan |
| Probuphenine |
| RBP-6000 |
| RX 6029M |
| RX-6029-M |
| SCHEMBL15821 |
| Sublocade |
| Suboxone? (TN) |
| Subutex |
| Subutex (TN) |
| Temgesic |
| Temgesic (TN) |
| UNII-40D3SCR4GZ |
| ZINC1319780 |
US Patents and Regulatory Information for PROBUPHINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braeburn Pharms Inc | PROBUPHINE | buprenorphine hydrochloride | IMPLANT;IMPLANTATION | 204442-001 | May 26, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Braeburn Pharms Inc | PROBUPHINE | buprenorphine hydrochloride | IMPLANT;IMPLANTATION | 204442-001 | May 26, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
International Patents for PROBUPHINE
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2005528422 | ➤ Sign Up |
| European Patent Office | 2561860 | ➤ Sign Up |
| European Patent Office | 1509182 | ➤ Sign Up |
| Japan | 4668611 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
